Back to search

Peptide record

TPDB07257

Antibacterial Antiviral Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07257
Antibacterial Antiviral Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0 PD_Hemolysis
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Antiviral, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FFGKVLKLIRKIF
Physicochemical Analysis
C82H133N19O14
ANDCEQHMPSTWY
KF
1609.08
11.73
4
0
8
+4
-1.27
0.969
142.31
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
2
I
2
L
3
K
0
M
3
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 2 L: 2 K: 3 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
13
C82H133N19O14
1609.08
11.73
+4
-1.27
0.969
Evidence Records 8 records
Evidence 1 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against S. aureus USA300 MRSA (MIC 3.1 uM) and E.coli (MIC > 100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficiency Vir
Evidence 2 Activity

Activity

MIC
Antiviral
3.1 µM

Target

Staphylococcus aureus USA300 MRSA

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
active against S. aureus USA300 MRSA (MIC 3.1 uM) and E.coli (MIC > 100 uM) ( Menousek et al., 2012 ). inhibited Human Immunodeficiency Vir
Evidence 3 Activity

Activity

10% Hemolysis
Toxicity
16 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 16 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 4 Activity

Activity

LC50
Toxicity
128 µg/mL
Cytotoxic
LC50 | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 5 Activity

Activity

50% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
50% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 6 Activity

Activity

50% Cell death
Toxicity
6.78 µM
Cytotoxic
50% Cell death | 6.78 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 8 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis